Freelance/No affiliation.
J Med Ethics. 2017 Nov;43(11):730-736. doi: 10.1136/medethics-2016-104050. Epub 2017 Jun 6.
Many potential therapeutic agents are discarded before they are tested in humans. These are not quack medications. They are drugs and other interventions that have been developed by responsible scientists in respectable companies or universities and are often backed up by publications in peer-reviewed journals. These possible treatments might ease suffering and prolong the lives of innumerable patients, yet they have been put aside. In this paper, we outline a novel mechanism-the Plutocratic Proposal-to revive such neglected research and fund early phase clinical trials. The central idea of the Proposal is that any patient who rescues a potential therapeutic agent from neglect by funding early phase clinical trials (either entirely or in large part) should be offered a place on the trial.
许多潜在的治疗药物在进行人体试验之前就被淘汰了。这些不是庸医的药物。它们是由负责任的科学家在有信誉的公司或大学开发的药物和其他干预措施，并且通常有同行评议期刊的出版物支持。这些可能的治疗方法可以减轻无数患者的痛苦并延长他们的生命，但它们被搁置了。在本文中，我们概述了一种新颖的机制——富豪提案——来恢复这种被忽视的研究并为早期临床试验提供资金。该提案的核心思想是，任何通过为早期临床试验提供资金（全部或大部分）来挽救潜在治疗药物的患者都应该获得试验的机会。
